Amoxicillin 500 mg

Description

No description information is available for the specified drug.

Uses and Indications

Amoxicillin is indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the following conditions: upper respiratory tract infections, lower respiratory tract infections, skin and skin structure infections, urinary tract infections, acute otitis media, sinusitis, and for the eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence.

Amoxicillin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, as there are no adequate and well-controlled studies in pregnant women. However, it is not expected to cause any nonteratogenic effects in the fetus.

Dosage and Administration

The recommended route of administration for this medication is oral. The active ingredient is amoxicillin anhydrous, with a dosage of 500 mg.

Healthcare professionals should ensure that the medication is taken as prescribed, adhering to the specified dosage. It is important to instruct patients to take the medication with a full glass of water and to follow any additional guidelines provided regarding food intake, as this may affect absorption.

Dosing intervals and duration of therapy should be determined based on the specific condition being treated, the patient's response to therapy, and any relevant clinical guidelines. Regular monitoring of the patient's progress is advised to ensure the effectiveness of the treatment and to make any necessary adjustments.

Contraindications

Amoxicillin is contraindicated in patients with mononucleosis due to the potential for severe adverse reactions. Additionally, if an allergic reaction occurs, the administration of amoxicillin should be discontinued immediately, and appropriate therapeutic measures should be initiated.

Warnings and Precautions

Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving penicillin therapy, including amoxicillin. These reactions are particularly likely in individuals with a history of penicillin hypersensitivity or sensitivity to multiple allergens. In the event of an allergic reaction, amoxicillin must be discontinued immediately, and appropriate medical intervention should be initiated.

Clostridium difficile-associated diarrhea (CDAD) has been documented with the use of nearly all antibacterial agents, including amoxicillin. The severity of CDAD can range from mild diarrhea to life-threatening colitis. Clinicians should consider CDAD in any patient presenting with diarrhea following antibacterial treatment. If CDAD is suspected or confirmed, it may be necessary to discontinue ongoing antibiotic therapy not specifically targeting C. difficile.

Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection is unlikely to benefit the patient and may contribute to the emergence of drug-resistant bacteria. Additionally, a significant proportion of patients with mononucleosis who are treated with amoxicillin develop an erythematous skin rash; therefore, amoxicillin should not be administered to patients diagnosed with mononucleosis.

Prior to initiating therapy with amoxicillin, a thorough inquiry into the patient's history of hypersensitivity reactions to penicillins, cephalosporins, or other allergens is essential. It is important to note that treatment with antibacterial agents can disrupt the normal flora of the colon, leading to an overgrowth of C. difficile.

Clinicians should maintain a careful medical history, as CDAD has been reported to occur up to two months after the administration of antibacterial agents. If an allergic reaction occurs, amoxicillin should be discontinued, and appropriate therapy should be instituted. In cases where CDAD is suspected or confirmed, it is crucial to discontinue any ongoing antibiotic use not directed against C. difficile.

Side Effects

Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving penicillin therapy, including amoxicillin. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or sensitivity to multiple allergens.

Clostridium difficile associated diarrhea (CDAD) has been observed with the use of nearly all antibacterial agents, including amoxicillin. The severity of CDAD can range from mild diarrhea to fatal colitis. It is essential to consider CDAD in all patients who present with diarrhea following antibacterial use, as cases have been reported to occur over two months after the administration of antibacterial agents. A careful medical history is necessary to identify potential cases.

Prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection is unlikely to benefit the patient and may increase the risk of developing drug-resistant bacteria.

Additionally, a high percentage of patients with mononucleosis who receive amoxicillin develop an erythematous skin rash. Therefore, amoxicillin should not be administered to patients with mononucleosis.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

The table below lists all NDC Code configurations of Amoxicillin 500 mg (amoxicillin), the U.S. brand-name prescription product. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric use of amoxicillin has not been specifically detailed in the available prescribing information. There are no recommended age ranges, dosing differences, safety concerns, or special precautions for children provided in the insert. Healthcare professionals should consider this lack of specific pediatric data when prescribing amoxicillin to pediatric patients.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including age considerations, dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as they may have altered pharmacokinetics and pharmacodynamics. Monitoring for efficacy and safety is recommended in this population, given the potential for increased sensitivity to medications.

Pregnancy

Amoxicillin is contraindicated in pregnancy due to potential risks to the fetus associated with its use. The safety and efficacy of amoxicillin in pregnant women have not been established, and therefore, its use should be approached with caution.

Healthcare professionals should consider that dosage modifications may be necessary for pregnant patients. A careful assessment of the benefits versus risks of treatment is essential when considering amoxicillin for women of childbearing potential. It is important to weigh the potential fetal impacts against the therapeutic needs of the mother.

Lactation

There are no specific statements regarding the use of this medication in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the prescribing information regarding dosage adjustments, special monitoring, or safety considerations. Therefore, healthcare professionals should exercise caution when prescribing this medication to patients with reduced kidney function, as the lack of data necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in these patients, although specific recommendations are not provided.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. Healthcare professionals are advised to monitor patients closely for any signs of adverse effects or symptoms that may arise from excessive dosing.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Patients should be evaluated for potential complications, and appropriate interventions should be implemented based on clinical judgment.

For further guidance, healthcare professionals may refer to established protocols for managing drug overdosage or consult a poison control center.

Nonclinical Toxicology

No teratogenic effects have been reported in the available data. Additionally, there is no information regarding non-teratogenic effects. The nonclinical toxicology section does not provide any specific details. Furthermore, there is no information available concerning animal pharmacology and toxicology.

Postmarketing Experience

Serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, have been reported in patients receiving penicillin therapy, which encompasses amoxicillin.

Clostridium difficile-associated diarrhea (CDAD) has been documented with the use of nearly all antibacterial agents, including amoxicillin. The severity of CDAD can vary, ranging from mild diarrhea to fatal colitis. Notably, cases of CDAD have been reported to occur more than two months following the administration of antibacterial agents.

Patient Counseling

Healthcare providers should advise patients about the potential for serious and occasionally fatal hypersensitivity reactions, including anaphylaxis, associated with penicillin therapy, such as amoxicillin. It is essential to conduct a thorough inquiry regarding any previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens before initiating therapy with amoxicillin. Should an allergic reaction occur, patients must be instructed to discontinue amoxicillin immediately and seek appropriate medical intervention.

Providers should also inform patients about the risk of Clostridium difficile associated diarrhea (CDAD), which has been reported with the use of nearly all antibacterial agents, including amoxicillin. Patients should be made aware that CDAD can range in severity from mild diarrhea to potentially fatal colitis. It is crucial to consider CDAD in any patient presenting with diarrhea following antibacterial use. If CDAD is suspected or confirmed, ongoing antibiotic therapy not targeting C. difficile may need to be discontinued.

Additionally, healthcare providers should emphasize that prescribing amoxicillin in the absence of a proven or strongly suspected bacterial infection is unlikely to benefit the patient and may increase the risk of developing drug-resistant bacteria. Providers should also caution that a significant percentage of patients with mononucleosis who receive amoxicillin may develop an erythematous skin rash; therefore, amoxicillin should not be administered to patients diagnosed with mononucleosis.

Storage and Handling

The product is supplied in a tightly closed container to ensure integrity and stability. It should be stored at a temperature range of 20°C to 25°C (68°F to 77°F), with permissible excursions between 15°C to 30°C (59°F to 86°F). It is essential to protect the product from light to maintain its efficacy. Any unused portion should be discarded after opening to prevent contamination and ensure safety.

Additional Clinical Information

The medication is administered orally. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

FDA Insert (PDF)

This document is the official FDA-approved prescribing information for Amoxicillin 500 mg as submitted by Health Department, Oklahoma State. It includes detailed information about indications, dosage, contraindications, warnings, and clinical pharmacology.

View full prescribing information (PDF)